Aethlon Medical, Inc. (AEMD) announced that U.S. Patent No. 12,409,260, covering the use of its Hemopurifier for Long COVID treatment, will issue on September 9, 2025.
Additionally, Unitary European Patent No. 4136453, covering Hemopurifier use for COVID-19-associated coagulopathy (CAC), was granted on July 9, 2025.
The U.S. patent protects Hemopurifier applications in patients with reduced viral loads but persistent Long COVID symptoms beyond 12 weeks, as well as those requiring removal of circulating COVID-19 spike protein. The European patent covers its use in patients with CAC who no longer have detectable viral particles.
The U.S. patent will expire in 2042, with a 385-day extension, while the European patent runs until 2041.
CEO and CFO James Frakes said the patents strengthen the company's intellectual property in addressing unmet medical needs. He noted that while Hemopurifier remains in R&D for Long COVID, the protections provide a strong foundation for future therapeutic applications.
Wednesday, AEMD closed at $1.35, down 17.68%, and is trading flat after hours on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.